Detail akcie Spero Therapetcs Rg online

Business Summary: Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Spero Therapeutics Inc revenues decreased 23% to $25.5M. Net loss decreased 52% to $22.9M. Revenues reflect Grant revenue decrease of 63% to $5.5M, Collaboration revenue decrease of 96% to $12K. Lower net loss reflects United States segment loss decrease of 51% to $25.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.88 to -$0.41.